Sexual Health
PT-141 (Bremelanotide)
Your desire pathway, not your blood flow.
PT-141 is FDA-approved only for premenopausal women with hypoactive sexual desire disorder. Use for other purposes is off-label and not FDA-approved. Your provider reviews your file and confirms whether it's clinically appropriate for you.
Purchase type
Save 10% today and on every refill. Auto-renews at your selected cadence, pause or cancel anytime.
Cadence
Only available if prescribed after an online consultation with a licensed provider.
What's included
- ✓Medication and supplies
- ✓Provider visit and unlimited follow-ups
- ✓Free expedited shipping
- ✓Injection home kit included
Pause, change, or cancel anytime from your account.
This medication is prepared by a licensed compounding pharmacy. Compounded medications are not reviewed by the FDA for safety or effectiveness and are dispensed only after a licensed provider determines they are appropriate for you.
How it works
Your provider will explain PT-141 in terms of where it acts, not what it does to blood flow. Bremelanotide, the active compound, is an alpha-MSH analog that activates MC3R and MC4R receptors in your hypothalamus, part of the desire and arousal circuitry your brain runs through dopamine and oxytocin. It works nothing like a PDE5 inhibitor: no vascular effect, no spontaneous arousal created from nothing. You still need arousal cues present for it to do anything. Because the mechanisms don't overlap, some patients are prescribed PT-141 alongside a PDE5 inhibitor rather than as a substitute for one, on your provider's guidance.
What to expect
PT-141 is typically injected about 45 minutes before anticipated activity, with onset falling between 45 and 90 minutes and a window of effect lasting roughly 4 to 8 hours. The RECONNECT-1 and RECONNECT-2 trials, conducted in premenopausal women with hypoactive sexual desire disorder, found meaningful improvement in about 2 in 5 participants, compared with roughly 1 in 5 on placebo. Roughly 4 in 10 people using PT-141 experience nausea, most commonly in the two hours right after injecting, easing as treatment continues. Headache, a temporary blood pressure increase, injection-site reactions, and flushing round out the commonly reported effects, along with hyperpigmentation, skin, gum, or mole darkening that can develop with repeated use.
- ✓FDA-approved for premenopausal women with HSDD; your provider confirms where your use fits before prescribing
- ✓Acts on your brain's desire pathway through melanocortin receptors, not on blood flow
- ✓In the RECONNECT trials, about 40 percent of women reported meaningful improvement, versus roughly 20 percent on placebo
- ✓Your provider can pair it with a PDE5 inhibitor, since the two mechanisms run separately
Safety information
PT-141 is FDA-approved only for premenopausal women with hypoactive sexual desire disorder. Use for other purposes is off-label and not FDA-approved. This product is compounded by a licensed pharmacy and is not FDA-approved as dispensed. It has not undergone FDA review for safety or efficacy in that compounded form. PT-141 is off the table entirely if your blood pressure runs uncontrolled, or if bremelanotide has ever caused a hypersensitivity response for you. Your provider also factors in any history of cardiovascular disease, reduced liver or kidney function, and whether melanoma runs in your family or your own history, given the theoretical connection between the melanocortin pathway and melanoma risk. Because PT-141 can cause hyperpigmentation, darkening of the skin, gums, or moles, your provider will ask you to keep an eye on your moles and flag any changes. If your provider decides PT-141 isn't clinically appropriate for you, you won't be charged for the medication.
Frequently asked questions
Compounded medications are prepared by a US-licensed pharmacy and are not reviewed by the FDA for safety or effectiveness. Products are dispensed only after a licensed provider determines they are appropriate. Information here is educational and is not a substitute for medical advice.